Acute graft-versus-host disease (aGvHD) is a frequent complication after allogeneic bone marrow/stem cell transplantation (BMT/SCT) induced by co-transplanted alloreactive conventional donor T cells. We previously demonstrated that the adoptive transfer of donor CD4CD25Foxp3 regulatory T cells (Treg) at the time of BMT prevents aGvHD in murine models. Yet, the therapeutic potential of donor Treg for the treatment of established aGvHD has not yet been studied in detail. We now used in vitro expanded phenotypically and functionally stable murine Treg to explore their therapeutic efficacy in haploidentical aGvHD models. Upon transfer donor Treg ameliorate clinical and histologic signs of aGvHD and significantly improve survival. They migrate to lymphoid as well as aGvHD target organs, predominantly the gastrointestinal tract, where they inhibit the proliferation of conventional T cells, reduce the influx of myeloid cells, and the accumulation of inflammatory cytokines. Successfully treated animals restore aGvHD-induced tissue damage in target organs and lymphoid tissues, thereby supporting lymphocyte reconstitution. The therapeutically applied Treg population survives long term without conversion into pathogenic effector T cells. These results demonstrate that donor Treg not only prevent aGvHD, but are also efficacious for the treatment of this life-threatening BMT complication.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214258 | PMC |
| http://dx.doi.org/10.1038/s41375-019-0625-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.
Blood
January 2025
Stanford University Medical Center, Stanford, California, United States.
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy limited by graft-versus-host disease (GVHD). In preclinical studies and early-phase clinical studies enrichment of donor regulatory T cells (Tregs) appears to prevent GVHD and promote healthy immunity.We enrolled 44 patients on an open-label, single-center, phase 2 efficacy study investigating if a precision selected and highly purified Treg cell therapy manufactured from donor mobilized peripheral blood improves one-year GVHD-free relapse free survival (GRFS) after myeloablative conditioning (trial NCT01660607).
View Article and Find Full Text PDFSingle-cell transcriptome analysis of stem cells from human exfoliated deciduous teeth investigating functional heterogeneity in immunomodulation.
Sci Rep
December 2024
Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
Mesenchymal stem cells (MSCs) have been widely used in the treatment of various inflammatory diseases. The inadequate understanding of MSCs and their heterogeneity can impact the immune environment, which may be the cause of the good outcomes of MSCs-based therapy that cannot always be achieved. Recently, stem cells from human exfoliated deciduous teeth (SHED) showed great potential in inflammatory and autoimmune diseases due to their immature properties compared with MSCs.
View Article and Find Full Text PDFRegulatory T cell therapy is associated with distinct immune regulatory lymphocytic infiltrates in kidney transplants.
Med
December 2024
Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK. Electronic address:
Background: Adoptive transfer of autologous regulatory T cells (Tregs) is a promising therapeutic strategy aimed at enabling immunosuppression minimization following kidney transplantation. In our phase 1 clinical trial of Treg therapy in living donor renal transplantation, the ONE Study (ClinicalTrials.gov: NCT02129881), we observed focal lymphocytic infiltrates in protocol kidney transplant biopsies that are not regularly seen in biopsies of patients receiving standard immunosuppression.
View Article and Find Full Text PDFAnalysis of antigen specificity of Treg cell clonotypes expanded upon SARS-CoV-2 infection.
Int Immunol
December 2024
Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
The pandemic outbreak of SARS-CoV-2 has threatened human health worldwide. Among protective immune reactions, T cell responses are diverse among individuals, which is related to the differences in severity. A T cell subset, regulatory T (Treg) cells, is crucial for limiting excessive immune responses.
View Article and Find Full Text PDFRegulatory T cells promote decidual vascular remodeling and modulate uterine NK cells in pregnant mice.
JCI Insight
December 2024
Robinson Research Institute and School of Biomedicine, The University of Adelaide, Adelaide, Australia.
Article Synopsis
- Regulatory T (Treg) cells are crucial for maintaining immune tolerance during pregnancy, ensuring that the mother’s body accepts the developing fetus and placenta.
- In a study using a specific mouse model, researchers found that depleting Treg cells early in pregnancy led to problems with the remodeling of uterine arteries, reduced natural killer (uNK) cell numbers, and resulted in fetal loss and growth restriction.
- By transferring Treg cells from healthy donors, the negative effects on vascular function and fetal health were mitigated, highlighting the important role Treg cells play in adapting the uterine environment for a successful pregnancy and their connection to issues like preeclampsia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!